title: [Recent progress in treatment for multiple sclerosis].
abstract: Multiple sclerosis (MS) is currently considered to be an autoimmune disease mediated by myelin antigen-specific Th 1 cells. Although the mechanism of MS remains to be elucidated, new disease modifying drugs have recently been introduced to MS treatment. Interferon-beta, copolymer 1 and intravenous administration of immunoglobulins have been shown to significantly reduce the relapse rate, progression of disease and increase of MRI lesion load in MS. However, as the effects of these drugs are nonspecific immunomodulation, specific immunomodulation therapy for MS is called for. T cell vaccination, altered peptide ligand and oral tolerance are possible candidates for specific immune therapy for MS. As in Asians there is such a distinct subtype of MS as HLA-DPB 1 * 0501-associated opticospinal MS, it is important to look for unique immune therapy for opticospinal MS in future.
authors.affiliation: Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University.
authors.forename: J
authors.initials: J
authors.lastname: Kira
mesh_terms: D000068717:Glatiramer Acetate; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007167:Immunotherapy; D016899:Interferon-beta / Q000627:therapeutic use; D008213:Lymphocyte Activation / Q000276:immunology; D009103:Multiple Sclerosis / Q000276:immunology / Q000628:therapy*; D010455:Peptides / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology; D014612:Vaccines / Q000627:therapeutic use
chemical_list: D016756:Immunoglobulins, Intravenous; D010455:Peptides; D014612:Vaccines; D000068717:Glatiramer Acetate; D016899:Interferon-beta